Sanofi said it is preparing for life after Dupixent’s patent cliff by leaning on late-stage and commercial business development and M&A rather than a major overhaul of its R&D approach. Executives said the company wants to derisk assets scientifically and clinically while also leveraging its commercial capabilities. Speaking after reporting third-quarter results, Sanofi CEO Belén Garijo said the firm will use its cash flow and low leverage to fund transactions, particularly those positioned for near-to-mid commercialization. Sanofi CFO François Roger similarly highlighted access to external financing. The company posted €14.4 billion in net sales, with Dupixent up 34.8% to nearly €5.7 billion, and said full-year sales growth guidance moved to low-teens at constant currency. The update comes as Dupixent represented 39% of quarterly net sales, keeping the long-term dependence under focus for analysts. Sanofi also said vaccine sales fell 6.6% in the quarter, while Altuviiio helped support growth among its 13 launch products.